CTAD 2024 | Recommendations for the appropriate use of donanemab in Alzheimer’s disease

Suzanne Schindler, MD, PhD, Washington University School of Medicine in St. Louis, St. Louis, MO, discusses the current recommendations for the appropriate use of donanemab, the second disease-modifying drug for Alzheimer’s disease (AD). Preliminary recommendations suggest that individuals with mild symptoms and confirmed biomarkers for early AD are eligible for donanemab treatment. However, treatment is not recommended for individuals with a higher risk of amyloid-related imaging abnormalities (ARIA). Official recommendations are expected to be released in early 2025. This interview took place at the 17th Clinical Trials on Alzheimer’s Disease (CTAD) congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.